SLC1542 Protein, Human (HEK293, GFP-Strep-His)

The SLC15A2 protein is a proton-coupled amino acid transporter that prefers dipeptides and transports oligopeptides containing 2 to 4 amino acids. The stoichiometric ratio of protons to peptides is 2:1 or 3:1, which helps the kidneys absorb dipeptides and tripeptides. SLC1542 Protein, Human (HEK293, GFP-Strep-His) is the recombinant human-derived SLC15A2 protein, expressed by HEK293 , with C-GFP-Strep-His tag.

SLC15A2 protein, a proton-coupled amino-acid transporter, demonstrates a preference for transporting oligopeptides containing 2 to 4 amino acids, with a notable affinity for dipeptides. Its transport activity involves a proton to peptide stoichiometry of 2:1 or 3:1, facilitating the absorption of circulating di- and tripeptides from the glomerular filtrate within the kidney. Beyond its role in peptide transport, SLC15A2 exhibits versatility by transporting various substances, including beta-lactam antibiotics like cefadroxil, other antiviral and anticancer drugs, the dipeptide-like aminopeptidase inhibitor bestatin, and carnosine. Notably, its involvement in innate immunity extends to promoting the detection of microbial pathogens by NOD-like receptors (NLRs), and it mediates the transport of bacterial peptidoglycans across cellular membranes, such as muramyl dipeptide (MDP), a ligand for NOD2, particularly in macrophages.

Human

HEK293

C-His;C-Strep;C-GFP

Q16348 (N2-L729)

6565

Partial

NPFQKNESKETLFSPVSIEEVPPRPPSPPKKPSPTICGSNYPLSIAFIVVNEFCERFSYYGMKAVLILYFLYFLHWNEDTSTSIYHAFSSLCYFTPILGAAIADSWLGKFKTIIYLSLVYVLGHVIKSLGALPILGGQVVHTVLSLIGLSLIALGTGGIKPCVAAFGGDQFEEKHAEERTRYFSVFYLSINAGSLISTFITPMLRGDVQCFGEDCYALAFGVPGLLMVIALVVFAMGSKIYNKPPPEGNIVAQVFKCIWFAISNRFKNRSGDIPKRQHWLDWAAEKYPKQLIMDVKALTRVLFLYIPLPMFWALLDQQGSRWTLQAIRMNRNLGFFVLQPDQMQVLNPLLVLIFIPLFDFVIYRLVSKCGINFSSLRKMAVGMILACLAFAVAAAVEIKINEMAPAQPGPQEVFLQVLNLADDEVKVTVVGNENNSLLIESIKSFQKTPHYSKLHLKTKSQDFHFHLKYHNLSLYTEHSVQEKNWYSLVIREDGNSISSMMVKDTESRTTNGMTTVRFVNTLHKDVNISLSTDTSLNVGEDYGVSAYRTVQRGEYPAVHCRTEDKNFSLNLGLLDFGAAYLFVITNNTNQGLQAWKIEDIPANKMSIAWQLPQYALVTAGEVMFSVTGLEFSYSQAPSSMKSVLQAAWLLTIAVGNIIVLVVAQFSGLVQWAEFILFSCLLLVICLIFSIMGYYYVPVKTEDMRGPADKHIPHIQGNMIKLETKKTKL

≥ 90%, as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.